NOT FOR DISTRIBUTION
Header cover image

Biosino Bio-Technology and Science Incorporation

Market Cap

HK$217.1m

Last Updated

2021/04/11 10:16 UTC

Data Sources

Company Financials

Executive Summary

Biosino Bio-Technology and Science Incorporation, together with its subsidiaries, manufactures, sells, and distributes in-vitro diagnostic reagent products primarily in Mainland China. More Details


Snowflake Analysis

Imperfect balance sheet with questionable track record.

Share Price & News

How has Biosino Bio-Technology and Science Incorporation's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 8247 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: Insufficient data to determine 8247's volatility change over the past year.


Market Performance


7 Day Return

-10.7%

8247

-3.1%

HK Biotechs

-1.1%

HK Market


1 Year Return

-10.7%

8247

59.2%

HK Biotechs

28.6%

HK Market

Return vs Industry: 8247 underperformed the Hong Kong Biotechs industry which returned 59.2% over the past year.

Return vs Market: 8247 underperformed the Hong Kong Market which returned 28.6% over the past year.


Shareholder returns

8247IndustryMarket
7 Day-10.7%-3.1%-1.1%
30 Day-10.7%2.0%-1.8%
90 Day-10.7%7.1%3.4%
1 Year-10.7%-10.7%59.5%59.2%33.5%28.6%
3 Year-29.9%-38.8%-32.1%-33.3%4.0%-6.9%
5 Year-52.2%-61.3%-0.3%-4.0%48.7%23.7%

Long-Term Price Volatility Vs. Market

How volatile is Biosino Bio-Technology and Science Incorporation's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biosino Bio-Technology and Science Incorporation undervalued compared to its fair value and its price relative to the market?

67.28x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 8247's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 8247's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 8247 is poor value based on its PE Ratio (67.3x) compared to the HK Biotechs industry average (40.5x).

PE vs Market: 8247 is poor value based on its PE Ratio (67.3x) compared to the Hong Kong market (11.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8247's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 8247 is good value based on its PB Ratio (1x) compared to the HK Biotechs industry average (3.4x).


Future Growth

How is Biosino Bio-Technology and Science Incorporation forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

56.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biosino Bio-Technology and Science Incorporation has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Biosino Bio-Technology and Science Incorporation performed over the past 5 years?

-66.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8247 has a large one-off gain of CN¥9.2M impacting its December 31 2020 financial results.

Growing Profit Margin: 8247 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 8247 has become profitable over the past 5 years, growing earnings by -66.2% per year.

Accelerating Growth: 8247 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 8247 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (17.5%).


Return on Equity

High ROE: 8247's Return on Equity (-0.4%) is considered low.


Financial Health

How is Biosino Bio-Technology and Science Incorporation's financial position?


Financial Position Analysis

Short Term Liabilities: 8247's short term assets (CN¥386.5M) exceed its short term liabilities (CN¥378.9M).

Long Term Liabilities: 8247's short term assets (CN¥386.5M) exceed its long term liabilities (CN¥49.5M).


Debt to Equity History and Analysis

Debt Level: 8247's debt to equity ratio (97.7%) is considered high.

Reducing Debt: Insufficient data to determine if 8247's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 8247's debt is not well covered by operating cash flow (5.9%).

Interest Coverage: Insufficient data to determine if 8247's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is Biosino Bio-Technology and Science Incorporation current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 8247's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 8247's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8247's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8247's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 8247 is not paying a notable dividend for the Hong Kong market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 8247's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Yanglin Lin (38 yo)

0.67

Tenure

Mr. Yanglin Lin serves as the President of Biosino Bio-Technology and Science Incorporation since August 3, 2020. He serves as the executive director of New Journey Hospital Group Co., Ltd since February 2...


Leadership Team

Experienced Management: 8247's management team is considered experienced (2.9 years average tenure).


Board Members

Experienced Board: 8247's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biosino Bio-Technology and Science Incorporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biosino Bio-Technology and Science Incorporation
  • Ticker: 8247
  • Exchange: SEHK
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$217.061m
  • Shares outstanding: 144.71m
  • Website: https://www.sinobio.com.cn

Number of Employees


Location

  • Biosino Bio-Technology and Science Incorporation
  • No. 27, Chaoqian Road
  • Science and Technology Industrial Park
  • Beijing
  • 102200
  • China

Listings


Biography

Biosino Bio-Technology and Science Incorporation, together with its subsidiaries, manufactures, sells, and distributes in-vitro diagnostic reagent products primarily in Mainland China. It offers clinical c...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 10:16
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.